hkaraman, Author at Danforth Health

Insights

Built to Transact: Aligning for IPO, M&A, or Strategic Deals in Biotech

Expert insights contributed by Managing Directors Ted Raad and Candice Cantelli Meklis

For biotech companies, few moments are as pivotal as the period following meaningful clinical data. Positive results don’t just validate a program — they unlock optionality, whether an IPO, licensing deal, acquisition, or strategic partnership.

But optionality isn’t automatic.

The companies that successfully capitalize on this inflection point aren’t just clinically promising — they’re built to transact. They’ve aligned their operations, development strategy, and commercial story in a way that stands up to scrutiny from investors, partners, and acquirers alike.

Here’s what that alignment really requires.

1. Build Infrastructure that Withstands Diligence

Transaction readiness starts long before a deal process begins.

Investors and acquirers aren’t just evaluating your science — they’re assessing whether your company can operate at scale under public market or partner scrutiny. That means:

Financial rigor: Clean, auditable financials and forecasting discipline
Operational scalability: Systems and processes that won’t break under growth
Governance maturity: A board structure, controls, and documentation that hold up in diligence

Too often, companies wait until a financing or deal is imminent to address these areas. By then, gaps become risks — and risks can become discounts.

Just as importantly, transaction-ready companies are disciplined about where they spend. Sophisticated investors and acquirers increasingly reward lean operating models that direct capital toward value-generating activities — particularly high-quality clinical execution and meaningful data generation — rather than excessive fixed overhead. Companies that stay focused on milestone-driving investments often preserve more flexibility, stronger capitalization profiles, and broader strategic optionality.

2. Craft a Deal-Ready Asset Narrative

Great data doesn’t speak for itself.

Different stakeholders — public investors, large pharma partners, strategic acquirers — evaluate assets through different lenses. What they all need, however, is a clear, coherent, and defensible story.

That story should:

Translate clinical results into meaningful differentiation
Address risk head-on, not obscure it
Connect the asset to a larger strategic vision
Anticipate the questions diligence teams will ask — and answer them proactively

A strong narrative doesn’t just describe what you’ve done. It makes the case for why your asset will create value in the hands of the next owner or investor.

3. Align Development Strategy with Value Creation

Transaction readiness is shaped by the decisions you make before data readouts.

Program prioritization, indication selection, and trial design all influence how buyers and investors perceive value and flexibility.

Key considerations include:

Are you advancing the right indications to maximize strategic interest?
Do your studies generate data that is decision-grade for partners or regulators?
Are you preserving the ability to expand into additional indications or combinations?

Well-designed development programs don’t just answer scientific questions — they expand strategic options.

4. Demonstrate Real Market Potential

Clinical success alone is rarely enough to drive a premium outcome.

Stakeholders increasingly expect to see evidence that a therapy can win in the real world — not just in a trial.

That means translating clinical outcomes into:

Clear product positioning relative to standard of care
Evidence of payer relevance and reimbursement potential
Insights from key opinion leaders and patients that validate adoption potential

Early commercial thinking signals that your asset isn’t just viable — it’s valuable.

5. Preserve Optionality Across Strategic Paths

Perhaps the most overlooked element of transaction readiness is intentionality around optionality.

The goal isn’t to commit early to a single path — it’s to stay credible across multiple: IPO, licensing or co-development partnerships, and M&A.

This requires:

Disciplined capital allocation and timing around capital raises and partnerships
Avoiding decisions that limit future flexibility
Continuously evaluating how new data shifts your best strategic path

Companies that maintain optionality don’t just react to opportunities — they create leverage.

Transaction Readiness Is a Cross-Functional Effort

Being “built to transact” isn’t the responsibility of a single team. It sits at the intersection of:

Operational excellence
Clinical strategy
Commercial insight
Strategic storytelling

When these elements are aligned, companies don’t just reach inflection points — they’re prepared to act on them.

And in today’s environment, that preparation is often what separates a good outcome from a great one.

Are You Built to Transact?

Many companies don’t realize where their gaps are until they’re already in the middle of diligence — when it’s hardest to fix them.

At Danforth, we work with biotech teams across the full corporate lifecycle to assess and strengthen transaction readiness — from financial and operational infrastructure to asset positioning, development strategy, and commercial validation.

If you’re approaching a key inflection point, we can help you evaluate where you stand and what it will take to maximize your options.

Insights

Why HCP Engagement Can Make or Break an Ultra-Rare Disease Launch

Insights from Chris Mycek, Head of Commercialization at Benchworks, a Danforth Health Company

Launching in an ultra-rare disease market is not a volume game. Success depends on whether the right physicians have the confidence, clarity, and support to identify patients, initiate treatment, and continue prescribing.

That is what makes healthcare professional (HCP) engagement so critical.

In broader specialty markets, commercial teams can often rely on scale and repetition to build awareness and drive adoption. In ultra-rare disease, the equation is different. Prescriber universes are small, treatment decisions are highly nuanced, and each account can materially influence launch performance. When uptake falls short, the issue is often not awareness alone. More often, it is a gap in confidence, coordination, or capability.

A recent case study involving the launch of a first-in-class therapy for a rare pediatric metabolic disorder highlights this dynamic.

When Awareness is Not Enough

A mid-sized biotechnology company launched a therapy for a rare pediatric metabolic disorder affecting roughly 2,000 patients in the United States. The product entered the market with strong Phase 3 efficacy data and favorable payer coverage. On paper, the launch appeared well-positioned.

Yet in the first 18 months, revenue significantly underperformed projections.

Commercial analysis showed the company had correctly identified its core prescriber base: approximately 85 pediatric metabolic specialists. But actual prescribing was concentrated among just 22 of them.

The remaining specialists were aware of the therapy but hesitant to act. Their concerns centered on patient selection, timing of treatment initiation, comfort with the novel mechanism of action, potential long-term safety considerations, and uncertainty around insurance coverage and out-of-pocket costs. Some also viewed the therapy as relevant only for the most severe phenotypes rather than the broader eligible population.

This pattern is common in ultra-rare disease.

Awareness may open the door, but it rarely drives adoption on its own. In highly specialized markets, prescribing decisions require deeper clinical confidence, practical support, and coordinated engagement across functions.

A More Targeted Intervention

Working with Benchworks, a Danforth Health Company, the organization implemented a six-month HCP engagement program focused on sharper targeting and stronger field coordination.

The strategy our experts facilitated centered on five key moves.

1. Refining segmentation beyond simple prescriber lists

The team developed a more dynamic targeting model based on patient volume, growth potential, and alignment with treatment philosophy. In ultra-rare disease, effective segmentation must go beyond static prescriber lists to identify the accounts most likely to drive near-term adoption.

2. Enabling peer-to-peer learning

The company launched small-group dinners and virtual roundtables featuring active prescribers sharing real-world clinical experience. This peer-to-peer model helped move physicians from awareness to greater confidence in patient selection and treatment initiation.

3. Tightening MSL and field integration

Weekly account planning sessions improved coordination between MSLs and field teams, enabling more aligned and responsive engagement. In ultra-rare disease, seamless medical-commercial collaboration is essential to delivering credible, timely support.

4. Addressing access concerns directly

The company developed payer-specific guidance and hub services talking points to address coverage and affordability questions. Clear access communication helped reduce friction between prescription intent and therapy start.

5. Supporting treatment initiation with practical tools

The launch team created clinical support materials, including dosing algorithms, monitoring protocols, and adverse event guidance. These resources helped physicians feel more prepared to initiate treatment with confidence.

The Impact of Coordinated HCP Engagement

Within six months of engagement with our experts, the company saw meaningful improvement across key launch metrics:

Active prescribers increased from 22 to 58

New patient starts rose 47% quarter over quarter

Prescription abandonment fell from 23% to 11%

Time from first prescription to second prescription dropped from 8.3 months to 4.7 months

Net revenue increased 12% year over year despite flat pricing

The takeaway is clear: when commercial teams address the specific barriers holding physicians back, adoption can accelerate meaningfully even in a small, highly specialized market.

Looking to Strengthen Launch Performance?

From launch planning to HCP engagement strategy, Danforth Health’s commercial readiness experts help life sciences companies build smarter launch strategies, align cross-functional teams, and accelerate adoption in complex markets.

Reach out to our team today.

Insights

Get Ahead of Risk: How Integrating Regulatory Early Drives Commercial Impact in Life Sciences

Expert insights from Lisa Maffei Luther, Founder and Head of Regulatory Strategy at Advyzom, a Danforth Health company

For many biopharma companies, regulatory is often viewed as a critical – but contained – function: essential for approval, but less central once a product reaches the market.

In reality, regulatory plays an increasingly strategic role in how a product is communicated, adopted, and sustained over time.

From the earliest stages of commercialization planning through post-approval lifecycle management, regulatory sits at the intersection of science, compliance, and commercial impact. And when that connection isn’t fully integrated, companies can face real consequences — slower launches, inconsistent messaging, or increased regulatory risk.

The growing complexity of commercial regulatory

Today’s commercialization environment is more complex than ever:

Promotional claims must be not only compelling, but fully aligned with evolving labeling and guidance
Pre-launch scientific exchange requires careful navigation to avoid crossing into promotion
Global considerations introduce additional layers of variability and risk
Post-approval changes — from new indications to safety updates — require ongoing coordination across teams

At the same time, commercial teams are under pressure to move quickly, differentiate clearly, and engage stakeholders effectively.

Balancing these dynamics isn’t easy, and it’s no longer something that can be managed in silos.

Regulatory as a bridge — not a checkpoint

The most effective organizations are shifting their mindset: Regulatory isn’t just a checkpoint at the end of the process — it’s a strategic partner throughout.

When regulatory is embedded early and works closely with commercial, medical, and market access teams, it can:

Shape messaging strategies that are both impactful and compliant
Translate complex labeling into clear, usable claims
Anticipate and mitigate risk before it slows down execution
Streamline review processes and reduce rework
Support consistent, aligned communication across functions and markets

In this model, regulatory becomes a driver of efficiency and clarity, not just a gatekeeper.

The overlooked importance of post-approval strategy

Just as critical, and often underappreciated, is the role of regulatory after approval.

Maintaining a product’s value in-market requires continuous attention to:

Labeling updates and evolving safety information
Post-marketing requirements and commitments
New data, indications, or formulations
Shifts in the regulatory landscape

Without a proactive approach, these factors can create friction, delay opportunities, or even impact patient access.

With the right strategy in place, however, they become opportunities to extend value, strengthen positioning, and ensure continuity of care.

A more integrated path forward

As commercialization models evolve, the line between regulatory and commercial execution continues to blur.

Companies that succeed will be those that treat regulatory not as a constraint — but as an enabler of smarter, more effective commercialization.

That means building more integrated teams, aligning earlier in the process, and taking a lifecycle view of both compliance and value creation.

Because in today’s environment, getting regulatory right isn’t just about avoiding risk — it’s about unlocking the full potential of your product.

Insights

Most Favored Nation (MFN) Drug Pricing: Market Access Implications and Manufacturer Preparedness

What Is MFN?

A Most Favored Nation (MFN) drug pricing policy would tie certain U.S. drug prices (most likely within Medicare) to the lowest price paid for the same product in a basket of comparable, economically advanced countries.

Rather than relying solely on domestic benchmarks such as Average Sales Price (ASP), MFN models use international reference pricing (IRP) to cap U.S. reimbursement levels

While MFN is not currently in effect, variations of the policy have been proposed multiple times and remain a recurring theme in federal drug pricing discussions. In a post-IRA environment where Medicare negotiation is already reshaping pricing dynamics, MFN represents a potential next phase of pricing reform.

Why MFN Matters for Market Access

MFN is not simply a pricing policy. It fundamentally changes the interplay between global pricing strategy and U.S. access dynamics.

Historically:

U.S. pricing has been largely insulated from international pricing decisions
Market access strategy in the U.S. focused primarily on payer mix, contracting, and value demonstration domestically

Under MFN:

Global pricing decisions directly influence U.S. reimbursement
Ex-U.S. launch sequencing and pricing strategy become U.S. access decisions
Market access planning must shift from domestic optimization to global coordination

This creates both operational complexity and strategic risk.

Key Market Access Impacts

1. Global Launch Sequencing Becomes a U.S. Access Lever

If U.S. Medicare reimbursement is pegged to the lowest international price:

Early lower-price agreements in EU markets could reduce U.S. reimbursement ceilings
Delays in ex-U.S. launches may become more common
Manufacturers may prioritize price stability over speed to global access

Market Access Implication:
Launch sequencing, traditionally a commercial strategy decision, becomes a critical component of U.S. access preservation.

2. Increased Pressure on Gross-to-Net Strategy

MFN could effectively cap top-line pricing:

Reduced flexibility to offset domestic rebates with higher list prices
Potential compression of net revenue if international reference prices are significantly lower
Greater scrutiny of contracting structures across both Medicare and commercial segments

Market Access Implication:
Manufacturers will need tighter integration between pricing, contracting, and policy teams to manage cross-market impacts

3. Impact on Medicare Negotiation Leverage

If MFN is layered onto IRA price negotiation:

The “maximum fair price” ceiling could be influenced by international pricing floors
Negotiation dynamics may shift toward even greater federal leverage
Therapeutic classes with strong ex-U.S. HTA pressure (e.g., oncology, immunology) could see disproportionate exposure

Market Access Implication:
Access teams must prepare for negotiations that incorporate international comparators more explicitly and aggressively.

4. Formulary and Utilization Management Ripple Effects

Lower Medicare reimbursement rates could:

Change buy-and-bill economics in Part B
Affect provider margin and prescribing behavior
Influence payer formulary positioning in Part D

If margins compress:

Providers may prefer alternative therapies with better economics
Access hurdles may increase if plans attempt to offset reimbursement compression elsewhere.

Market Access Implication:
Manufacturer field reimbursement and provider engagement strategies will need to adapt quickly

Manufacturer Decision-Making Under MFN Risk

Even before implementation, MFN risk affects strategic planning. Manufacturers should be incorporating MFN into scenario modeling now

1. Portfolio Risk Stratification

Companies should assess:

Which assets are most exposed to international price referencing?
Which therapeutic areas face the largest EU-U.S. price deltas?
Which products are most Medicare-dependent?

This enables:

Prioritized mitigation planning
Revenue-at-risk modeling
Earlier lifecycle management interventions

2. Integrated Global Pricing Governance

MFN requires tighter alignment across:

U.S. market access
Global pricing & reimbursement
Government affairs
Legal and compliance

Decisions that were once siloed (e.g., a German price agreement) may have direct downstream U.S. impact

Prepared organizations will:

Establish formal cross-market price governance committees
Model international pricing agreements before execution
Create scenario playbooks for reference price compression

3. Enhanced Economic Value Demonstration

As pricing ceilings tighten, value demonstration becomes even more critical:

Stronger real-world evidence (RWE)
More robust health economic modeling
Outcomes-based contract readiness
Clear differentiation from therapeutic alternatives

Under MFN, margin compression increases the importance of maintaining favorable access tiers and minimizing utilization restrictions.

4. Contracting Innovation and Risk Sharing

If top-line pricing flexibility narrows:

Manufacturers may shift toward outcomes-based agreements
Indication-specific pricing may gain traction
Population health-based contracting could become more common

Access teams should be developing infrastructure now to support:

Data collection and analytics
Outcomes measurement
Performance-based reimbursement models

5. Scenario Planning and Financial Modeling

MFN preparedness requires:

Modeling various international basket configurations
Estimating price floors under different country mixes
Stress-testing gross-to-net assumptions
Evaluating provider economics impact (especially in Part B)

This modeling should inform:

Investor communications
Portfolio prioritization
Pipeline investment decisions

Preparedness Checklist for Market Access Teams

Manufacturers should consider the following actions:

Strategic Planning

☐ Conduct MFN exposure modeling by product

☐ Quantify Medicare revenue at risk

☐ Map international price differentials across key markets

Governance

☐ Formalize cross-market pricing review processes

☐ Establish escalation protocols before signing major ex-U.S. agreements

☐ Align U.S. and global access leadership

Evidence & Value

☐ Strengthen RWE generation plans

☐ Prepare enhanced HEOR dossiers

☐ Expand outcomes-based contracting readiness

Operational Readiness

☐ Assess provider reimbursement impact

☐ Update field reimbursement training

☐ Develop payer communication strategies

MFN may or may not materialize in its current form, but the direction of travel in U.S. drug pricing policy is clear: increased scrutiny, global benchmarking, and tighter reimbursement controls. Organizations that wait for final rules before acting risk being structurally unprepared.

Is your portfolio exposed to MFN risk?

At Danforth Health, we work with manufacturers to model policy exposure, align global and U.S. pricing strategy, pressure-test access assumptions, and build practical readiness plans. If MFN, or broader international reference pricing, would materially affect your portfolio, now is the time to assess your exposure and build a coordinated response.

Schedule a conversation with our experts to evaluate your MFN exposure and build a readiness strategy.

Insights

AI in Clinical Outsourcing: What’s Signal, What’s Noise?

Written by Rene Stephens, Managing Director, Clinical Business Operations, Danforth Health

AI in clinical development is everywhere right now. Headlines promise transformation. Vendors promise acceleration. Teams are running pilots.

But beneath the noise, where does the industry actually stand?

To better understand the reality, Danforth Health conducted a focused industry pulse survey both before the 2026 SCOPE Summit Conference and during a live panel discussion with Outsourcing, Clinical Operations, and healthcare Innovation experts on The Impact of AI on Outsourcing and Clinical Trial Execution. The findings provide a candid snapshot of adoption, constraints, and where real value is (and isn’t) emerging.

View the survey results here and continue reading for the 5 biggest takeaways…

1. AI Adoption Is Real — but Still Fragmented

Survey respondents confirmed that AI is no longer theoretical in clinical development, yet enterprise-wide adoption remains the exception, not the rule.

22% report actively using AI in a subset of trials

30% are implementing or formally allowing AI use

37% are still evaluating

Nearly 90% of organizations are somewhere on the adoption curve, but most remain in pilot mode, functional silos, or narrowly defined use cases rather than scaled transformation.

The takeaway: AI credibility has arrived. Operational maturity has not.

2. Deployment Is Concentrated Where Risk Is Measurable

Where AI is being deployed, the survey shows strong clustering around activities with:

High data density

Clear quality metrics

Auditable outputs

Respondents reported AI usage primarily in:

Data capture and quality oversight

Protocol design and optimization

Patient population and cohort identification

CSR preparation and submission support

Adoption is split between internally built tools and vendor/CRO-provided solutions, raising a strategic question many sponsors are still debating:

Is AI a capability to own, or a service to buy?

3. The Business Case Is Speed — Not Headcount Reduction

One of the clearest signals from both survey responses and the panel discussion:

AI’s value is being measured in cycle-time compression, not FTE elimination.

External benchmarks point to an average six-month reduction in development timelines per asset driven by:

Improved protocol feasibility

Faster cohort identification

Earlier quality signal detection

Sponsors are not viewing AI as a replacement for CROs or clinical teams. Instead, it’s emerging as an execution accelerator, a tool to reduce rework, friction, and downstream risk.

4. Governance, Not Technology, Is the Primary Bottleneck

The biggest obstacles aren’t algorithmic; they’re organizational and are likely more difficult to overcome without a deliberate approach to change management.

Transparent positioning of the impact to current and future functions, both positive and potentially negative, and honest discussions with key stakeholders to address changes to operating processes and team roles, among others, are key considerations for POC pilots as well as full implementation.

Despite optimism, respondents expressed clear confounders to value:

Unclear ownership across Clinical Ops, IT, Data Science, and Procurement

Variability in CRO AI maturity and transparency

Questions around validation, auditability, and regulatory defensibility

At the same time, ICH E6(R3) and the FDA Diversity Action Plan (effective January 1, 2026) will increasingly force sponsors to integrate AI into risk-based quality management and enrollment analytics, whether they feel operationally ready or not.

In short: AI adoption is no longer optional, but unmanaged adoption is risky.

5. 2026–2027 Will Separate Experimenters from Operators

The survey reinforces a forward-looking conclusion:

Organizations can realize measurable gains in speed and predictability, and possibly see cost savings when AI is embedded into core trial design and operations (i.e., feasibility, site ID, data management, safety reporting, etc.)

Those that treat AI as an “innovation sidecar” risk falling behind, even if they run more pilots

This is less about tools and more about operating model design:

Sponsor-led vs. CRO-led AI

Centralized vs. functional deployment

Governance that enables scale without slowing execution

My Thoughts?

This industry pulse survey’s results tell a clear story:

AI in clinical trials has crossed the credibility threshold—but not the execution threshold.

The next phase will be defined less by better algorithms and more by better integration:

Into outsourcing strategy

Into vendor governance

Into clinical operating models

That is where real competitive advantage will be created.

If your team is navigating similar decisions around AI adoption and governance, we’d welcome the opportunity to compare perspectives. Reach out for a brief follow-up discussion to explore how your approach aligns with broader industry trends.

Insights

Commercial Planning: Building the Right Launch Team & Governance Model

Expert insights from Asymmetry Group, a Danforth Health Company

Product launches are amongst the most complex undertakings for biopharma companies—and there’s no shortcut to success. No matter how strong your strategy or detailed your plan, success ultimately depends on people. If you don’t have the right team in place, even the best-designed launch will fall short. That’s why launch governance and team structure aren’t just operational necessities; they’re strategic levers. Organizations that invest in building a high‑performing launch team and a governance model tailored to their unique needs don’t just execute—they create a competitive advantage.

Several considerations will shape your launch team structure and governance—and directly influence who you select, how the team operates, and what support they’ll need:

1) Launch Experience

Is this your company’s first launch? How much launch experience exists within your organization?

Implications: Internal experience will impact the level of expertise required on the team, whether you need to bring in external support, and how much structure and oversight your governance model must provide.

2) Desired Launch Team Dynamics

To what extent do you expect your team to operate as an integrated, cross‑functional group? Is this consistent with your current culture?

Implications: Your desired team dynamic will shape role selection, behavioral expectations, and whether new ways of working are needed to enable strong cross‑functional collaboration. Even if you have a highly experienced launch team, it’s likely the first time THIS TEAM is launching together.

3) Organizational Decision-Making

How does your organization collaborate and make decisions? Is authority centralized or shared across empowered teams? Are decisions made quickly or more slowly?

Implications: Existing decision-making patterns will inform governance design—defining authority levels, escalation pathways, meeting cadence, and required functional representation to maintain momentum. And then it’s up to the organization to live these decisions to create trust and efficiency.

4) Partnerships

Are external partners involved in the launch? What is the structure of the relationship, and how could it affect planning and execution?

Implications: Partnership arrangements will influence team composition, require clearly defined roles and responsibilities, and may necessitate additional coordination or joint governance mechanisms.

While there’s no single approach to structuring your launch team and governance, four best practices consistently position organizations for success:

1) Appoint a Launch Lead Who Bridges Strategy and Execution

This role varies by company and launch, but the Launch Lead must flex between strategic and execution‑focused work while maintaining a strong cross‑functional lens. Launch success requires alignment across all functions—not the efforts of just one or two teams.

2) Establish a Small, Expert Launch Management Team (LMT) to Drive Progress

Typically composed of the Launch Lead and a few launch‑experienced resources, the LMT drives critical work: shaping strategy, coordinating across teams, tracking progress, and flagging risks. Acting as the “quarterback” of the launch, the LMT ensures visibility, timely communication, and cross‑functional alignment.

3) Create a Lean, Empowered Governance Structure that Can Scale

Your model should include a Core Launch Team, Extended Launch Team, Steering Committee, and functional working teams. Core Launch Team members—one per key function—must be empowered decision‑makers who effectively communicate back to their functions. Keep the Core Team lean; leverage the Extended Launch Team to involve additional functions without slowing down execution. The Steering Committee plays a critical role by resolving escalations and making timely decisions that cannot be addressed within the Core Team, Extended Team, or individual functions.

4) Define Roles and Ways of Working to Enable Alignment and Decision‑Making

Roles and responsibilities should be clearly defined across all governance groups. Equally important is aligning on ways of working early—how decisions will be made, how escalations will be handled, how information will be shared, and what each governance member is accountable for.

Planning your next launch?

Building the right team and governance model is just the beginning. Whether you’re launching for the first time or bringing deep experience to a new organizational or market context, our workshop offers actionable insights, proven best practices, and practical tools to set you up for success.

Join us on March 26^th and 27^th and learn from our team of launch experts. Reserve your spot today: http://bit.ly/4eP0153 or reach out to our experts here.

Insights

Biotech Goal Setting: Why It’s a Mistake to Wait for the Board Meeting

We hear it all the time in biotech goal setting: “We can’t set goals until the Board signs off on our corporate strategy.”

The problem? That board meeting often doesn’t happen until February. By then, you’ve lost two of your twelve months and momentum.

At Danforth Health, we’ve worked with more than 1,8000 life science companies. One of the most common missteps we see is delaying biotech goal setting until everything is “finalized”. This hesitation leads to operational drift and signals to your team that alignment and accountability are negotiable. They aren’t.

Start Early. Adjust Later.

Even if your corporate strategy isn’t finalized yet, you can, and should, begin laying the groundwork for effective goal setting in biotech well before the calendar flips to January.

“You can always adjust. You can always modify. But if you wait to begin until everything is finalized, you’ve already fallen behind.” Danforth Advisors HR Experts

A Rolling Approach to Biotech Goal Setting

Begin in December: Host departmental and individual goal-setting sessions using current KPIs, performance metrics, and known priorities. This helps create momentum while keeping teams focused.

Use a Rolling Framework: When corporate goals are finalized post-board meeting, refine existing goals- don’t restart the process. This prevents duplication of effort and supports better alignment.

Train Managers to Guide the Process: Not everyone is naturally skilled at facilitating effective goal-setting conversations. And in biotech, where teams are lean and leaders wear many hats, that matters. Invest in manager enablement so that goal conversations are structured, consistent, and clear.

“A lot of the conversations we see around goal setting are vague. You want clarity on outcomes, not just tasks. Managers need to know how to distinguish between the two.” – Danforth Advisors HR Experts

Best Practices for Biotech Goal Setting

Use SMART Goals: Make them Specific, Measurable, Achievable, Relevant, and Time-bound. In biotech, metrics matter- especially when tied to funding, product development, and hiring plans.

Limit Company-Wide Goals to 3–5: Especially at the early stage, less is more. Trying to pursue too many priorities dilutes focus. Danforth Health consistently sees better execution when companies narrow down to a handful of core, high-impact goals.

Distinguish Goals from Tasks: A goal is a measurable outcome (e.g., “Complete IND submission by Q3”). A task is a step toward that goal (e.g., “Draft protocol outline”). Confusing the two can muddy accountability and derail timelines.

Cascade and Align: Once corporate goals are in place, ensure every department and employee understands how their work contributes to the larger mission. Alignment isn’t automatic- it’s built through communication and iteration.

What Happens After You Set Goals?

Effective biotech goal setting doesn’t stop once objectives are written down. Make it a living process:

Revisit them monthly or quarterly
Identify gaps, changing priorities, or resource constraints
Adjust without starting from scratch
Review progress transparently with leadership and staff

Need Help Setting Goals in Biotech?

At Danforth Health, we help biotech companies operationalize clarity-turning strategic priorities into measurable, achievable goals at every level. Don’t let the calendar or boardroom delay your momentum. Reach out today.

Insights

Mastering CRO Selection in 2026: A Biotech’s Strategy for Lower Risk and Better Outcomes

Insights by Rene Stephens, Managing Director, Danforth Advisors, a Danforth Health Company

As we dive into 2026, the stakes for biotech development have never been higher, and a disciplined CRO selection strategy for biotechs has shifted from a competitive advantage to a survival requirement. Capital markets remain unpredictable, the pharma patent cliff continues to reshape partnership dynamics, and regulators are increasing scrutiny around vendor oversight, data integrity, and AI-enabled trial technologies.

At the same time, CROs are navigating consolidation, capacity fluctuations, and geopolitical pressures, creating new execution risks even for well-prepared sponsors. In this environment, selecting the wrong CRO can derail entire programs, jeopardize valuation, and undermine investor confidence. That’s why more biotechs are partnering with outsourcing experts who bring data-driven frameworks, real-time market visibility, and negotiation power to one of the most consequential decisions in drug development.

Why Engage Outsourcing Experts Now

Navigate the Transformed CRO Landscape

Assess rapidly consolidating global players and their post-M&A service quality

Evaluate emerging regional CROs responding to geopolitical shifts and supply chain diversification

Identify niche providers with specialized therapeutic expertise

Distinguish CROs truly investing in AI/ML capabilities from those simply marketing them

Track financially stable providers amid industry volatility

Maximize Capital Efficiency (Still Non-Negotiable in 2026)

Extract maximum value from every development dollar with follow-on funding still uncertain

Leverage real-time CRO pricing intelligence as the market recalibrates

Negotiate favorable terms despite limited leverage in a constrained vendor ecosystem

Structure flexible payment terms aligned with funding milestones and runway

Utilize creative deal structures (risk-sharing, milestone-based payments) as CROs compete for quality projects

De-Risk in a Zero-Margin Environment

Apply rigorous evaluation processes when the timeline slips or trial failures are unaffordable

Identify red flags in operational capacity—resource constraints remain widespread

Assess vendor financial stability as some CROs continue to face economic pressures

Build contractual protections against geopolitical risk and supply chain disruptions

Secure Strategic Contract Terms

Performance accountability: SLAs with meaningful consequences for delays

Financial protections: Milestone payments, earn-backs, and sponsor-friendly advance structures

Flexibility: Clear change order processes to prevent scope creep

Personnel commitments: Lock in key team members to avoid bait-and-switch scenarios

Termination rights: Sponsor-favorable terms given the asymmetric risk profile

Rate caps: Protection against inflation and arbitrary cost escalations

Access Real-Time Market Intelligence

Know which CROs are hungry for work vs. operating at capacity

Track regulatory enforcement trends affecting timelines and budgets

Navigate decentralized/hybrid trial models and supporting technologies

Evaluate vendor experience with current FDA/EMA expectations and evolving guidances

Optimize Internal Resources

Free clinical operations teams to focus on execution rather than vendor management

Avoid learning-curve mistakes that resource-constrained teams cannot afford

Accelerate decision-making when speed-to-clinic determines competitive position

Maintain objectivity and avoid legacy or relationship-based CRO decisions

Leverage True Negotiating Power

Benefit from outsourcing experts’ market volume and relationships

Access pattern recognition from hundreds of CRO negotiations

Know what contract terms are worth pushing for vs. industry standard

Reduce legal spend through streamlined expert-led negotiations

A Modern CRO Selection Strategy for Biotechs Is No Longer Optional

In a year defined by operational risk, regulatory pressure, and intense competition for high-quality vendors, having a rigorous CRO selection strategy for biotechs is essential. Small biotechs must execute flawlessly with limited capital and compressed timelines.

You can’t afford to learn CRO selection through trial and error.

Danforth Health’s seasoned experts can help you make selection and contracting decisions that protect your program, preserve your capital, and position you for success. Contact our team today.

Insights

If You’re Going to JPM, Make it Count.

Breaking Bad Biotech: Practical Advice for Highly Effective Biotech Organizations

Expert insights from Gregg Beloff, Co-Founder and Managing Director of Danforth Health.

If you’ve ever been to the JP Morgan Healthcare Conference, you know it’s less a conference and more a Jungleland – a place where the hopeful and the hardened all show up looking for a breakthrough. The energy is electric, the pace is relentless, and every conversation feels like it could change your company’s trajectory.

But from a CFO’s chair, it’s also something else: an enormous investment. Flights, hotels, receptions, prep work, opportunity cost — the tab adds up fast. If you’ve decided to attend, you must make the investment count.

JPM can be one of the highest-ROI weeks of your year or an expensive blur that drains both capital and focus. The difference lies in your purpose and your planning.

Treat JPM like a strategic investment

Think of JPM as an asset class in your annual operating plan. Before spending a dollar or booking a meeting, define what success looks like in measurable terms.

Start by defining your objectives: are you raising capital, building partnerships, or increasing visibility ahead of a milestone? Each goal requires a different playbook and different KPIs. For example:

Investor ROI: How many qualified, decision-making investors will you meet?
Partnership traction: Which BD conversations could realistically lead to follow-up diligence?
Visibility return: Which events or moments get your story in front of the right audiences?

Just like any investment, JPM needs a thesis and a disciplined approach to executing it.

Focus on Yield, Not Volume

It’s easy to fall into the JPM trap of equating busy with productive. Back-to-back meetings look impressive on paper, but not all of them will actually move the needle.

The best outcomes derive from fewer, more strategic conversations that align with your financing or partnering objectives.

Vet every meeting: Is this a potential investor, or an information-gathering analyst?
Confirm who’s actually attending: decision-maker or screener?
Leave room for recalibration and reflection: time is capital, too.

The week’s real winners are rarely the busiest people in the lobby. They’re the ones whose calendars were curated with purpose.

Manage the Signal-to-Noise Ratio

JPM week is chaos: receptions stacked on panels stacked on hallway introductions. Ask yourself:

Which events actually align with your company’s capital or BD strategy?
Where will your CEO or CBO’s time have the greatest multiplier effect?
What can wait for quieter weeks, when inboxes and attention spans have cleared?

Think portfolio theory: not every opportunity deserves investment.

Make every dollar work harder

Treat JPM the way you’d approach any capital-intensive project — with discipline and intent.

Craft a crisp narrative: Tie your science to your strategy and your strategy to value creation. Investors should understand your story in two minutes flat.
Pre-plan your follow-ups: Don’t just “circle back.” Assign accountability for post-conference momentum.
Invest in presence wisely: Sometimes being seen in the right room creates more value than being everywhere at once.

Efficiency isn’t about doing less. It’s about ensuring every dollar and every hour generates tangible returns.

Close the loop

After JPM, debrief like you would after closing a financing round.

What relationships advanced your fundraising or partnership goals?
What intel will shape your capital or communications strategy?
Did the outcomes justify the spend?
What are the follow-ups/next steps, and who is accountable?

Treating JPM as a measurable investment — rather than an annual ritual — is how you turn noise into signal and activity into results.

The Bottom Line

In biotech, every decision is an investment — of time, attention, and capital. Treat JPM with the same financial discipline and focus you’d apply to any major investment. In a place where everyone’s chasing opportunity, the companies that win are the ones that plan, measure, and execute with purpose and intent.

Learn more about Danforth Health and connect with our expert team.

Insights

Talent Gaps & Layoffs in Biotech: Navigating the New Reality

Over the past two years, the biotech sector has weathered a difficult correction. Funding constraints and pipeline reprioritizations have led to waves of layoffs, creating leaner teams across the industry. Yet even as companies downsize, the need for specialized expertise has never been greater. The result is a widening talent gap – one that threatens productivity, continuity, and innovation.

Leaders at small and mid-sized biotech companies are being forced to make tough decisions: how to preserve institutional knowledge, sustain development momentum, and remain competitive with limited internal bandwidth.

Here are five takeaways for companies navigating this new workforce landscape:

1. Prioritize Core Expertise, Outsource the Rest

Not every role needs to be rebuilt internally. Identify which functions are critical to your intellectual property, regulatory strategy, or investor value story – and consider trusted external partners for everything else. Strategic outsourcing can allow you to execute on your business strategy while preventing burnout, reducing fixed costs, and ensuring continuity through development inflection points.

2. Reassess Organizational Design for Agility

Lean doesn’t have to mean overextended. Reassess how decisions have been made and consider if a smaller team could mean a more efficient approach, where bottlenecks exist, and which functions are duplicative. Flattening structures and empowering cross-functional project leads can help maintain momentum even with smaller teams.

3. Invest in Retention – Even When You’re Cutting Costs

After layoffs, there is often undesirable attrition, and the remaining team members often carry heavier workloads and higher stress. Retention depends on transparency, recognition, and growth opportunities. Simple actions, like reviewing and updating roles and responsibilities, consistent communication about company direction, flexible work arrangements, or development stipends, can have an outsized impact on morale and loyalty.

4. Bridge Skill Gaps Through Partnerships and Interim Talent

Specialized expertise in areas like regulatory strategy, CMC, bioinformatics, and clinical operations is increasingly scarce. Interim or fractional experts can bridge capability gaps without the long-term cost of full-time hires, allowing your team to have the right level and amount of expertise as needed. If you are embracing a fractional model, look for experienced consultants or partner firms who understand biotech’s unique regulatory and operational nuances.

5. Revisit Workforce Planning Every Quarter

Embrace a just-in-time hiring model. While there is great talent in the market right now, hiring too far ahead of your needs can unnecessarily accelerate your cash burn. The market is shifting fast. What seemed essential six months ago may not be today. Building a rolling 3- to 6-month talent roadmap—aligned with your pipeline milestones and financing horizon—helps avoid reactionary hiring or deep cuts later on.

The Bottom Line

The biotech talent landscape is being reshaped in real time, but the need for great talent never goes away. In today’s environment, success will depend on strategic resourcing, organizational agility, and empathetic leadership. Companies that balance cost discipline with a thoughtful approach to people management will emerge stronger, more focused, and ready to capture opportunity as the market rebounds.

Danforth Health uniquely bridges both sides of the talent challenge — providing fractional experts to fill critical functional gaps. Our team can work with you to determine if a fractional resource is right for your business or if this is the time to invest in a full-time hire. Either way, we have the expertise and network to assess your needs, recruit the appropriate resources, and support their onboarding in a way that thoughtfully integrates them into your team quickly and efficiently.

Click here to schedule a free consultation about how we can support your talent needs.